Home Use of Closed-loop Insulin Delivery for Overnight Glucose Control in Adults with Type 1 Diabetes: a 4-week, Multicentre, Randomised Crossover Study
Overview
Authors
Affiliations
Background: Closed-loop insulin delivery is a promising option to improve glycaemic control and reduce the risk of hypoglycaemia. We aimed to assess whether overnight home use of automated closed-loop insulin delivery would improve glucose control.
Methods: We did this open-label, multicentre, randomised controlled, crossover study between Dec 1, 2012, and Dec 23, 2014, recruiting patients from three centres in the UK. Patients aged 18 years or older with type 1 diabetes were randomly assigned to receive 4 weeks of overnight closed-loop insulin delivery (using a model-predictive control algorithm to direct insulin delivery), then 4 weeks of insulin pump therapy (in which participants used real-time display of continuous glucose monitoring independent of their pumps as control), or vice versa. Allocation to initial treatment group was by computer-generated permuted block randomisation. Each treatment period was separated by a 3-4 week washout period. The primary outcome was time spent in the target glucose range of 3·9-8·0 mmol/L between 0000 h and 0700 h. Analyses were by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT01440140.
Findings: We randomly assigned 25 participants to initial treatment in either the closed-loop group or the control group, patients were later crossed over into the other group; one patient from the closed-loop group withdrew consent after randomisation, and data for 24 patients were analysed. Closed loop was used over a median of 8·3 h (IQR 6·0-9·6) on 555 (86%) of 644 nights. The proportion of time when overnight glucose was in target range was significantly higher during the closed-loop period compared to during the control period (mean difference between groups 13·5%, 95% CI 7·3-19·7; p=0·0002). We noted no severe hypoglycaemic episodes during the control period compared with two episodes during the closed-loop period; these episodes were not related to closed-loop algorithm instructions.
Interpretation: Unsupervised overnight closed-loop insulin delivery at home is feasible and could improve glucose control in adults with type 1 diabetes.
Funding: Diabetes UK.
Automated Insulin Delivery in Adults With Type 2 Diabetes: A Nonrandomized Clinical Trial.
Pasquel F, Davis G, Huffman D, Peters A, Parker J, Laffel L JAMA Netw Open. 2025; 8(2):e2459348.
PMID: 39951268 PMC: 11829226. DOI: 10.1001/jamanetworkopen.2024.59348.
A Systematic Review of Commercial Hybrid Closed-Loop Automated Insulin Delivery Systems.
Peacock S, Frizelle I, Hussain S Diabetes Ther. 2023; 14(5):839-855.
PMID: 37017916 PMC: 10126177. DOI: 10.1007/s13300-023-01394-5.
Kang S, Hwang Y, Kwon J, Kim S Diabetol Metab Syndr. 2022; 14(1):187.
PMID: 36494830 PMC: 9733359. DOI: 10.1186/s13098-022-00962-2.
Current Status and Emerging Options for Automated Insulin Delivery Systems.
Forlenza G, Lal R Diabetes Technol Ther. 2022; 24(5):362-371.
PMID: 35099302 PMC: 9131039. DOI: 10.1089/dia.2021.0514.
Current Advances of Artificial Pancreas Systems: A Comprehensive Review of the Clinical Evidence.
Moon S, Jung I, Park C Diabetes Metab J. 2021; 45(6):813-839.
PMID: 34847641 PMC: 8640161. DOI: 10.4093/dmj.2021.0177.